05/28/2014 - 8:57am

Looking to reinvent the specialty patient experience, CVS Caremark has announced that its Specialty Connect prescription services program is now available at all CVS/pharmacy locations.

05/27/2014 - 10:47am

A series of new clinical studies released Tuesday found that Cardinal Health Specialty Solutions’ Clinical Pathways program reduces the cost of cancer treatment, improves clinical care and shows promise for guiding treatment of other high-cost, complex diseases beyond cancer.

05/15/2014 - 3:13pm

On May 5 to 9, Armada Health Care hosted its 10th Annual Specialty Pharmacy Summit at the Wynn Hotel in Las Vegas, Nevada.

05/13/2014 - 12:57pm

KVK-Tech, a developer, manufacturer and marketer of specialty pharmaceuticals, announced the appointment of Joseph Lefebvre as VP business development, marketing and API sourcing.

05/12/2014 - 1:36pm

With half of all patients not taking their medications as prescribed, efforts to engage patients more effectively and boost adherence rates have become critical for pharmacy leaders. Here, we discuss how CVS Caremark is addressing the challenge with William Shrank, M.D. the company’s chief medical officer for provider innovation and analytics.

05/12/2014 - 10:36am

Lundbeck and Chelsea Therapeutics International last week announced an agreement under which Lundbeck will acquire Chelsea.

05/09/2014 - 2:25pm

A panel of speakers from all facets of health care convened yesterday to discuss the growth of the specialty pharmaceuticals industry during the 10th Annual Specialty Pharmacy Summit & Expo, hosted by Armada Health Care.

05/07/2014 - 11:21am

The pace of annual global spending on oncology medicines — which is approaching the $100 billion threshold — has moderated over the past five years, even as a surge in innovative and targeted therapies has brought new therapeutic options to the growing number of patients being treated for cancer and as survival rates for most tumor types continue to increase, according to a new report released Tuesday by the IMS Institute for Healthcare Informatics.

05/06/2014 - 2:54pm

Sandoz recently announced that the generic manufacturer continues to advance its biosimilars pipeline that currently has six molecules in the Phase III clinical trial/filing prep phase.